EGFR-Mutated Stage IV Lung Adenocarcinoma With Painful Finger Lesions During Osimertinib

This lung cancer diagnosis at a glance

Stage at diagnosis
Stage IV
Subtype
Adenocarcinoma
Biomarkers
EGFR-mutated; EGFR T790M-positive at relapse
Sex
Female
Treatment
targeted therapy and chemotherapy
Outcome
Care Ongoing

Treatment course, step by step

  1. She received erlotinib, gemcitabine, and pemetrexed in sequence, leaving minimal disease.
  2. After the right perihilar mass enlarged and rebiopsy found EGFR T790M, she started osimertinib.
  3. Osimertinib continued while painful finger lesions were managed with colloidal oatmeal.

What happened, in summary

A 61-year-old woman had Stage IV EGFR-mutated lung adenocarcinoma. At presentation, imaging showed a right upper-lobe nodule, a right perihilar mass, and a right pleural effusion. She received several single-agent treatments in sequence, including erlotinib, gemcitabine, and pemetrexed, after which only minimal disease remained.

Later imaging showed that the right perihilar mass had enlarged. A repeat biopsy confirmed relapsed disease and identified the EGFR T790M mutation, so osimertinib was started.

About 1 month into osimertinib, she developed painful cut-like lesions on the tips and palms of several fingers, with dryness near the nail beds. The lesions progressed across multiple fingers and interfered with daily activities. Examination found linear ulcers about 1 cm long and areas of dry, scaly skin.

Colloidal oatmeal provided partial relief. She continued osimertinib, and the finger lesions remained bothersome but controlled with regular topical treatment.

Where this story comes from

This is a lay summary of an account first published by PMC / PubMed Central. Read the original in full

How we source and attribute stories Accuracy and limitations

Collections this story belongs to

Similar lung cancer stories

These are lay summaries of published cancer stories, for information only. No two cancers behave the same way, and nothing here predicts your own diagnosis or replaces advice from your oncology team. Read the full disclaimer

Search more lung cancer stories